High-Frequency rTMS Over the DLPFC for Chronic Low Back Pain
CompletedNot applicableNCT07468799
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Neuropathic pain is a chronic condition that significantly affects quality of life and often responds poorly to conventional pharmacological treatments. Repetitive transcranial magnetic stimulation (rTMS) has emerged as a non-invasive neuromodulation technique with potential analgesic effects. This study aimed to evaluate the effectiveness of rTMS in reducing neuropathic pain intensity among patients with confirmed neuropathic pain. A clinical study was conducted involving adult patients who met diagnostic criteria for neuropathic pain. Participants received rTMS sessions targeting the motor cortex over a defined treatment period. Pain intensity was assessed using standardized pain scales before and after treatment. The study examined changes in pain scores following rTMS therapy and evaluated its potential as an adjunctive treatment for neuropathic pain. The findings of this study may contribute to understanding the therapeutic role of rTMS in the management of neuropathic pain and support its use as a non-invasive treatment option.
Study details
- Official title
- High-Frequency Repetitive Transcranial Magnetic Stimulation Over the Dorsolateral Prefrontal Cortex Enhances IL-10 and Reduces Pain in Chronic Low Back Pain: A Randomized Controlled Trial
- Conditions
- Interventions
- Sponsor
- Hasanuddin University
- Start date
- 2024-01-01
- Primary completion
- 2024-12-01
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Indonesia
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Adults aged 18-65 years * Diagnosed with schizophrenia according to DSM-5 criteria * Experiencing neuropathic pain or chronic pain symptoms * Stable psychiatric medication for at least 4 weeks prior to enrollment * Able to provide written informed consent Exclusion Criteria: * History of epilepsy or seizure disorders * Presence of metallic implants in the head * Severe neurological disorders * Substance abuse within the past 6 months * Pregnancy or breastfeeding * Contraindications to rTMS therapy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07468799